In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews (11/2009)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Inflammation: A Hot Space Gets Complicated," features profiles of CellAct Pharma, Kineta and Lycera. Plus these Start-Ups Across Health Care: BioLeap, Integrated Diagnostics, Nightingale-EOS, SBIO, Spirus Medical and Varix Medical.

You may also be interested in...

Spirus Medical Inc.

Spirus Medical Inc. has developed spiral endoscopy technology that it says enables better access to the gastrointestinal tract for diagnosing and treating GI disorders. The company's platform converts rotational movement into forward advancement, causing its devices to be drawn into, rather than pushed into the body.

Varix Medical Corp.

Varix Medical Corp.'s novel approach to treating chronic venous insufficiency, better known as varicose veins, uses endovenous water vapor (steam) instead of surgical stripping, radiofrequency energy or laser light to shrink and destroy veins. The start-up's goal is to be the only company to offer a minimally invasive technology that treats most of the veins in the legs, unlike competing modalities that are limited to treating one type of varicose vein.

Nightingale-EOS Ltd.

Nightingale-EOS Ltd.'s Beam Profile Reflectometry technology evaluates coatings on medical devices by measuring the interference effects caused by the interaction of light reflecting from the coating surface with that from the substrate surface. The company's first focus is on implanted cardiac devices, primarily drug-eluting stents, where BPR can measure the concentration of the drug within the film of the coating.

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts